Welcome to our dedicated page for Cooper news (Ticker: COO), a resource for investors and traders seeking the latest updates and insights on Cooper stock.
CooperCompanies (NYSE: COO) delivers essential updates from the forefront of medical device innovation through its CooperVision and CooperSurgical divisions. This hub provides investors and healthcare professionals with direct access to official announcements, including product developments, regulatory milestones, and strategic initiatives shaping the vision care and women's health sectors.
Find curated press releases covering earnings results, clinical trial updates, and market expansion activities. Track innovations in silicone hydrogel contact lenses and fertility treatment technologies alongside analysis of industry trends impacting COO's global operations. Our repository simplifies monitoring of key developments across 130+ countries where Cooper's life-enhancing devices serve patients and providers.
Bookmark this page for real-time updates on FDA clearances, acquisition activity, and leadership changes. Subscribe to alerts for breaking news about COO's specialty lens portfolio and reproductive health solutions maintaining its position as a medical technology leader.
CooperCompanies (NYSE: COO) reported a 15% decline in fiscal Q3 revenue to $578.2 million, with CooperVision and CooperSurgical revenues falling 12% and 24%, respectively. GAAP diluted EPS was $1.12, down 53% year-over-year, while non-GAAP diluted EPS decreased 30% to $2.28. Despite COVID-19 challenges, the company noted a faster-than-anticipated recovery and provided Q4 revenue guidance of $665-$693 million. Operating and gross margins also saw reductions, attributed to heightened COVID-related expenses. The debt at the end of the quarter stood at $1.88 billion, with cash equivalents of $127.4 million.
CooperCompanies (NYSE: COO) will participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 23, 2020, at 3:20 pm ET. Senior Vice President and CFO Brian Andrews will represent the company in a virtual session. Investors can access the session via a webcast available on the Investor Relations section of Cooper's website. CooperCompanies operates through two main units: CooperVision, focusing on vision care, and CooperSurgical, dedicated to women's health and fertility. The company has over 12,000 employees globally.
CooperVision has announced Sarah Michelle Gellar as the spokesperson for its Brilliant Futures™ Myopia Management Program, aimed at increasing awareness of myopia among children. The program features the MiSight® 1 day lens, FDA-approved to slow myopia progression in children aged 8-12. With myopia affecting over 40% of Americans, CooperVision emphasizes the importance of early intervention during a time of increased screen usage.
The campaign includes national advertising and collaboration with the National Association of School Nurses to educate parents about myopia management.
CooperCompanies (NYSE: COO) will participate in the Morgan Stanley Virtual 18th Annual Global Healthcare Conference on September 16, 2020, with Senior VP and CFO Brian Andrews leading the presentation starting at 2:45 pm ET. Interested investors can access the session via a webcast on Cooper's Investor Relations website.
Cooper operates globally with two main units: CooperVision, focusing on vision care products, and CooperSurgical, dedicated to women's health and fertility solutions. The company has over 12,000 employees and products available in more than 100 countries.
CooperCompanies (NYSE: COO) will participate in the 2020 Wells Fargo Virtual Healthcare Conference on September 10, 2020, at 1:20 pm ET. CEO Al White will represent the company during this session. A webcast of the presentation will be available on the Investor Relations section of Cooper's website, ensuring accessibility for stakeholders and investors. CooperCompanies is a global medical device firm operating through CooperVision and CooperSurgical, focusing on vision care and women's health products with a workforce exceeding 12,000 across more than 100 countries.
CooperCompanies (NYSE: COO) will announce its third quarter 2020 financial results on September 3, 2020, at 4:15 PM ET. Following the release, a conference call will take place at 5:00 PM ET to discuss these results and other corporate developments. Interested participants can join the call by dialing 855-643-4430 (U.S.) or 707-294-1332 (International) with the passcode 'Cooper'. A simultaneous webcast will be available on the company's website, and a recording will be accessible from September 3 through September 10, 2020.
CooperCompanies (NYSE: COO) has declared a semi-annual dividend of 3 cents per share, payable on August 7, 2020, to stockholders of record on July 23, 2020. This decision aligns with the company's commitment to pay annual dividends as approved by its board of directors. CooperCompanies operates through two key divisions: CooperVision, focused on vision care products, and CooperSurgical, dedicated to women's health and fertility solutions, with products available in over 100 countries.
CooperCompanies announced the appointment of Holly Sheffield as President of CooperSurgical, effective July 13, 2020, following the retirement of Robert Auerbach. Auerbach will remain in an advisory role until February 1, 2021. Sheffield has been with Cooper since June 2018 as Executive VP and Chief Strategy Officer, previously serving at UBS Securities LLC. CEO Albert White expressed confidence in Sheffield's leadership capabilities, highlighting a seamless transition ahead for the company.
CooperCompanies (NYSE: COO) reported a 20% decline in revenue for Q2 2020, totaling $524.9 million, impacted by the COVID-19 pandemic. CooperVision's revenue decreased 17% to $402.2 million, while CooperSurgical saw a 28% drop to $122.7 million. GAAP diluted EPS fell 91% to $0.23, while non-GAAP EPS was $1.51, down 48%. Operating margins dropped significantly to 5% from 22% year-over-year. The company has suspended its fiscal year 2020 guidance due to uncertainty.
CooperCompanies (NYSE: COO) plans to release its second quarter 2020 financial results on June 4, 2020, at 4:15 PM ET. A conference call will follow at 5:00 PM ET to discuss results and corporate developments. Investors can join via dial-in or a webcast available on the CooperCompanies website. A recording of the call will be accessible from June 4 at 8:00 PM ET until June 11, 2020. Cooper operates through CooperVision and CooperSurgical, focusing on vision care and women's health.
FAQ
What is the current stock price of Cooper (COO)?
What is the market cap of Cooper (COO)?
